




Supplementary Fig. S1. Swimmer plot of post-switch follow-up. Each horizontal bar represents one patient, starting from the time of switch (time 0). Blue bars indicate patients who remained in remission, while red bars represent those who discontinued treatment. A black triangle marks the time of relapse. Patients are ordered by time to event or, for censored cases, by the length of observed follow-up.

Supplementary Table S1. Detailed clinical and therapeutic characteristics of patients undergoing infliximab switching. Continuous variables are expressed by median and interquartile range, whereas categorical variables are expressed by percentage.

Patient	Patient characteristics at diagnosis			
	Age, y, sex	Positive HLA-B51	Clinical manifestations	Treatment regimens, except for IFX
1	27, M	1	Oral and genital ulcers, ocular (uveitis and retinal vasculitis) involvement, intestinal tract lesions, arterial and venous involvement	PDN, AZA, CsA, ADA
2	43, M	0	Oral ulcers, ocular (chorioretinitis, retinal vasculitis) involvement, arthritis	PDN, Clc, CsA
3	26, M	-	Oral and genital ulcers, intestinal tract lesions, venous involvement	PDN, CsA, MTX
4	39, F	1	Oral and genital ulcers, skin lesions (erythema nodose), CNS, intestinal tract lesions, PNS	PDN, AZA, CsA, MTX, TCZ
5	41, M	1	Oral ulcers, CNS and ocular (uveitis) involvement	PDN
6	17, M	-	Oral and genital ulcers, ocular involvement, arthritis	PDN, Clc, CsA, MTX, HCQ
7	22, M	0	Oral and genital ulcers, arthritis (sacroiliitis)	PDN, Clc
8	40, F	0	Oral ulcers, skin lesions, arthritis, sacroiliitis	PDN, AZA, CsA, MTX, ADA
9	28, F	0	Oral and genital ulcers, skin lesions, CNS and ocular (uveitis, retinal vasculitis) involvement	PDN, ADA, MMF
10	38, F	1	Oral ulcers, skin lesions, ocular (uveitis, retinal vasculitis) involvement, arthritis	PDN, Clc, AZA, MTX, ADA

ADA: adalimumab; APL: apremilast; AZA: azathioprine; Clc: colchicine; CNS: central nervous system; CsA: cyclosporine, CYC: cyclophosphamide, IFX: infliximab; MMF: mycophenolate mofetil; MTX: methotrexate; PDN: prednisone; PNS: peripheral nervous system; SEC: secukinumab; TCZ: tocilizumab; UST: Ustekinumab.